A new review by Laura Shannon and colleagues examines the pathogenesis of pulmonary fibrosis and links evolving mechanistic insights to current and emerging therapeutic strategies.
Read now in BMJ Medicine: https://bit.ly/3REaoRH
Current treatment for pulmonary fibrosis is limited to nintedanib and pirfenidone, which slow but do not halt or reverse the progression of the disease. These treatments are widely used globally. Emerging agents, such as nerandomilast, showed positive r...
